Viyash Scientific quarterly results

Q1 FY27 · Apr–Jun 2026

₹ crore	Q1 FY27	Q1 FY26	Change
Revenue	946	441	+114.4%
EBITDA	178	52.2	+241.8%
EBITDA margin	18.9%	11.8%	+7.0 pts
Profit before tax	112	25.5	+340.5%
Net profit	79.3	17.6	+351.3%
EPS	₹1.51	₹0.57	+164.9%

Every quarter

₹ crore except per share

Tap a line for its trend	Q1 FY27Jun 2026	Q4 FY26Mar 2026	Q3 FY26Dec 2025	Q2 FY26Sep 2025	Q1 FY26Jun 2025	Q4 FY25Mar 2025	Q3 FY25Dec 2024	Q2 FY25Sep 2024	Q1 FY25Jun 2024	Q4 FY24Mar 2024	Q3 FY24Dec 2023	Q2 FY24Sep 2023	Earlier quartersAlpha Plus

Expenses
	946	920	858	424	441	402	391	369	390	361	329	346	Earlier quartersEvery year the company has filed comes with Alpha Plus.
	8.3	15.9	14.0	2.2	3.9	1.7	5.8	4.5	2.7	4.0	4.5	1.6
	955	936	872	426	445	403	397	373	393	365	334	348
	402	364	347	183	180	159	170	135	153	166	146	157
	65.4	92.0	56.6	45.1	52.1	36.6	41.8	66.0	68.2	41.4	38.2	49.7
	−33.5	−43.1	−12.9	−14.8	2.8	4.1	−9.2	−6.0	−7.0	−13.2	−3.3	−16.5
	163	150	138	81.7	79.1	76.8	75.2	67.0	62.1	62.2	57.9	66.4
	12.5	14.5	16.8	13.5	14.2	15.1	15.0	14.3	16.4	12.4	12.6	12.6
	61.8	60.4	58.5	15.5	15.1	16.1	17.0	17.1	16.3	16.5	15.5	15.4
	171	173	154	73.5	75.6	78.9	78.6	67.2	71.9	72.2	68.6	74.7
	842	811	758	397	419	387	388	361	381	358	335	359
	178	184	176	55.7	52.2	46.2	34.5	39.1	42.0	32.3	22.2	15.1
	117	124	117	40.2	37.1	30.1	17.5	22.0	25.7	15.8	6.8	−0.2
Profit
	112	125	114	28.9	26.8	16.7	8.4	12.2	12.0	7.3	−1.3	−11.2
	0.0	0.0	−41.3	−1.7	−1.3	−0.3	−0.3	−4.3	0.0	−4.7	2.8	8.1
	112	125	73.1	27.2	25.5	16.3	8.1	7.9	12.0	2.6	1.5	−3.1
	34.0	29.3	−27.4	7.2	13.6	12.9	8.8	8.0	11.2	3.4	4.5	17.7
	−0.9	29.6	52.0	0.3	−5.7	−7.0	−7.2	−6.4	−8.2	−2.1	−13.7	−13.9
	33.1	58.9	24.6	7.6	8.0	5.9	1.6	1.6	2.9	1.4	−9.2	3.8
	79.3	66.4	48.5	19.6	17.6	10.4	6.5	6.3	9.1	1.3	10.7	−6.9
	79.3	66.4	48.5	19.6	17.6	10.4	6.5	6.3	9.1	1.3	10.7	−6.9
	−6.3	39.0	2.9	14.4	31.8	46.8	−56.9	19.3	−30.8	−21.7	4.8	−15.3
	73.0	105	51.4	34.0	49.3	57.1	−50.4	25.6	−21.7	−20.4	15.5	−22.2
	65.9	52.1	38.4	14.7	14.3	9.3	3.4	—	6.5	−0.9	8.3	−8.4
	13.4	14.3	10.1	4.9	3.3	1.1	3.0	—	2.6	2.2	2.4	1.5
Per share
	₹1.51	₹1.20	₹0.89	₹0.59	₹0.57	₹0.37	₹0.14	₹0.10	₹0.26	−₹0.04	₹0.33	−₹0.34
	₹1.47	₹1.17	₹0.87	₹0.58	₹0.56	₹0.36	₹0.13	₹0.10	₹0.26	−₹0.04	₹0.33	−₹0.34
Other comprehensive income — detail
	−6.3	39.0	2.9	14.4	31.8	46.8	—	—	—	—	—	—
	−0.4	−2.6	−0.5	0.0	0.0	−0.3	−0.0	−0.6	0.2	−1.1	−0.0	−0.1
	−0.1	−0.7	−0.1	0.0	0.0	−0.1	—	—	—	—	—	—
	—	—	—	—	—	—	−0.2	0.1	0.0	0.1	−0.0	−0.1
	−6.1	40.9	3.3	14.4	31.8	47.0	−57.1	20.0	−31.0	−20.5	4.8	−15.2
	60.3	79.7	38.3	27.0	42.3	54.6	−51.5	—	−23.6	—	12.1	−22.7
	12.7	25.7	13.1	6.9	7.1	2.5	1.1	—	1.9	—	3.4	0.5
Per share — as-filed variants
	₹1.51	₹1.20	₹0.89	₹0.59	₹0.57	₹0.37	₹0.14	₹0.10	₹0.26	−₹0.04	₹0.33	−₹0.34
	₹1.47	₹1.17	₹0.87	₹0.58	₹0.56	₹0.36	₹0.13	₹0.10	₹0.26	−₹0.04	₹0.33	−₹0.34
Derived — gross profit (revenue − materials − purchases − Δ inventories)
	512	507	467	211	207	202	188	173	176	167	149	156
	54.1%	55.1%	54.5%	49.7%	46.9%	50.3%	48.2%	47.0%	45.1%	46.1%	45.2%	45.1%
Adjusted (ex-exceptional items) — derived
	112	125	114	28.9	26.8	16.7	8.4	12.2	12.0	7.3	−1.3	−11.2
	0.0	0.0	−41.3	−1.7	−1.3	−0.3	−0.3	−4.3	0.0	−4.7	2.8	8.1
	79.3	66.4	75.9	20.8	18.4	10.6	6.7	9.8	9.1	3.5	7.9	−14.9
	₹1.51	₹1.20	₹1.39	₹0.63	₹0.60	₹0.38	₹0.15	₹0.15	₹0.26	−₹0.11	₹0.24	−₹0.74

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

VIYASH₹224.55

Viyash Scientific Ltd.

· Pharma & Health

Annual Quarterly₹ CrorePeersAARTIDRUGS YATHARTH THYROCARE SUPRIYA STAR SPARC SHILPAMED RUBICONMcap ₹9,809 Cr

View

In ₹ Crore except Per Share 3 Months Ending	Q2 FY24 30/09/2023	Q3 FY24 31/12/2023	Q4 FY24 31/03/2024	Q1 FY25 30/06/2024	Q2 FY25 30/09/2024	Q3 FY25 31/12/2024	Q4 FY25 31/03/2025	Q1 FY26 30/06/2025	Q2 FY26 30/09/2025	Q3 FY26 31/12/2025	Q4 FY26 31/03/2026	Q1 FY27 30/06/2026
Revenue from Operations	346.0	329.4	361.2	390.2	368.7	390.8	401.7	441.4	424.0	858.4	920.0	946.4
Other Income	1.6	4.5	4.0	2.7	4.5	5.8	1.7	3.9	2.2	14.0	15.9	8.3
Total Income	347.6	333.9	365.2	392.9	373.2	396.7	403.4	445.3	426.1	872.4	935.9	954.7
Expenses
+ Cost of Materials Consumed	156.6	145.7	166.4	153.1	135.3	169.9	159.0	179.7	182.8	347.3	363.9	402.3
+ Purchases of Stock-in-Trade	49.7	38.2	41.4	68.2	66.0	41.8	36.6	52.1	45.1	56.6	92.0	65.4
+ Changes in Inventories	-16.5	-3.3	-13.2	-7.0	-6.0	-9.2	4.1	2.8	-14.8	-12.9	-43.1	-33.5
+ Employee Benefit Expense	66.4	57.9	62.2	62.1	67.0	75.2	76.8	79.1	81.7	137.7	149.8	162.7
+ Finance Costs	12.6	12.6	12.4	16.4	14.3	15.0	15.1	14.2	13.5	16.8	14.5	12.5
+ Depreciation & Amortisation	15.4	15.5	16.5	16.3	17.1	17.0	16.1	15.1	15.5	58.5	60.4	61.8
+ Other Expenses	74.7	68.6	72.2	71.9	67.2	78.6	78.9	75.6	73.5	154.2	173.1	171.1
Total Expenses	358.8	335.1	357.9	380.9	360.9	388.2	386.7	418.5	397.3	758.1	810.6	842.3
EBITDA	15.1	22.2	32.3	42.0	39.1	34.5	46.2	52.2	55.7	175.6	184.3	178.4
EBIT	-0.2	6.8	15.8	25.7	22.0	17.5	30.1	37.1	40.2	117.1	123.8	116.6
Profit
PBT before Exceptional Items	-11.2	-1.3	7.3	12.0	12.2	8.4	16.7	26.8	28.9	114.3	125.2	112.4
+ Exceptional Items	8.1	2.8	-4.7	0.0	-4.3	-0.3	-0.3	-1.3	-1.7	-41.3	0.0	0.0
Pretax Income	-3.1	1.5	2.6	12.0	7.9	8.1	16.3	25.5	27.2	73.1	125.2	112.4
+ Current Tax	17.7	4.5	3.4	11.2	8.0	8.8	12.9	13.6	7.2	-27.4	29.3	34.0
+ Deferred Tax	-13.9	-13.7	-2.1	-8.2	-6.4	-7.2	-7.0	-5.7	0.3	52.0	29.6	-0.9
Tax Expense	3.8	-9.2	1.4	2.9	1.6	1.6	5.9	8.0	7.6	24.6	58.9	33.1
Net Income	-6.9	10.7	1.3	9.1	6.3	6.5	10.4	17.6	19.6	48.5	66.4	79.3
+ Net Income — Continuing Ops	-6.9	10.7	1.3	9.1	6.3	6.5	10.4	17.6	19.6	48.5	66.4	79.3
+ Other Comprehensive Income	-15.3	4.8	-21.7	-30.8	19.3	-56.9	46.8	31.8	14.4	2.9	39.0	-6.3
Total Comprehensive Income	-22.2	15.5	-20.4	-21.7	25.6	-50.4	57.1	49.3	34.0	51.4	105.4	73.0
Net Income to Common	-8.4	8.3	-0.9	6.5	—	3.4	9.3	14.3	14.7	38.4	52.1	65.9
Minority Interest	1.5	2.4	2.2	2.6	—	3.0	1.1	3.3	4.9	10.1	14.3	13.4
Per Share
Basic EPS	-0.34	0.33	-0.04	0.26	0.10	0.14	0.37	0.57	0.59	0.89	1.20	1.51
Diluted EPS	-0.34	0.33	-0.04	0.26	0.10	0.13	0.36	0.56	0.58	0.87	1.17	1.47
Other Comprehensive Income — detail
+ Other Comprehensive Income	—	—	—	—	—	—	46.8	31.8	14.4	2.9	39.0	-6.3
+ Items NOT to be Reclassified to P&L	-0.1	-0.0	-1.1	0.2	-0.6	-0.0	-0.3	0.0	0.0	-0.5	-2.6	-0.4
+ Tax on Items NOT to be Reclassified	—	—	—	—	—	—	-0.1	0.0	0.0	-0.1	-0.7	-0.1
+ Tax on Items NOT to be Reclassified — alt tag	-0.1	-0.0	0.1	0.0	0.1	-0.2	—	—	—	—	—	—
+ Items to be Reclassified to P&L	-15.2	4.8	-20.5	-31.0	20.0	-57.1	47.0	31.8	14.4	3.3	40.9	-6.1
Comprehensive Income — Owners of Parent	-22.7	12.1	—	-23.6	—	-51.5	54.6	42.3	27.0	38.3	79.7	60.3
Comprehensive Income — Non-controlling Interests	0.5	3.4	—	1.9	—	1.1	2.5	7.1	6.9	13.1	25.7	12.7
Per Share — as-filed variants
Basic EPS — Continuing Operations	-0.34	0.33	-0.04	0.26	0.10	0.14	0.37	0.57	0.59	0.89	1.20	1.51
Diluted EPS — Continuing Operations	-0.34	0.33	-0.04	0.26	0.10	0.13	0.36	0.56	0.58	0.87	1.17	1.47
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit	156.2	148.7	166.7	175.9	173.4	188.3	202.0	206.9	210.9	467.5	507.1	512.1
Gross Margin %	45.15	45.16	46.14	45.08	47.03	48.18	50.28	46.86	49.74	54.46	55.13	54.11
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)	-11.2	-1.3	7.3	12.0	12.2	8.4	16.7	26.8	28.9	114.3	125.2	112.4
− Exceptional Items (reconciliation)	8.1	2.8	-4.7	0.0	-4.3	-0.3	-0.3	-1.3	-1.7	-41.3	0.0	0.0
Net Income Adj (tax-effected)	-14.9	7.9	3.5	9.1	9.8	6.7	10.6	18.4	20.8	75.9	66.4	79.3
EPS Adj	-0.74	0.24	-0.11	0.26	0.15	0.15	0.38	0.60	0.63	1.39	1.20	1.51
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00
Paid Up Equity Capital	49.9	49.9	49.9	49.9	49.9	50.1	50.1	50.1	50.3	87.2	87.4	87.4

As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: Q1 FY27 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.

Viyash Scientific quarterly results

Viyash Scientific (NSE: VIYASH) has not yet announced the date of its Q2 FY27 results (July–September 2026); they are due by 14 November 2026 under SEBI's 45-day rule. Its latest results are for Q1 FY27 (April–June 2026). Consolidated net profit attributable to shareholders was ₹65.9 crore, up 360.3% from ₹14.3 crore in Q1 FY26 and up 26.4% from ₹52.1 crore in Q4 FY26. Revenue from operations was ₹946 crore, up 114.4% year on year and up 2.9% from the previous quarter.

Q2 FY26 results (a year earlier): 14 November 2025
Q1 FY27 results (the latest): 11 August 2026

Latest results: Q1 FY27 (Apr–Jun 2026) · consolidated

Q2 FY27 results due by: 14 November 202645 days after the quarter (SEBI)
Q1 FY27 net profit: ₹65.9 Cr+360.3% vs Q1 FY26+26.4% vs Q4 FY26
Q1 FY27 revenue: ₹946 Cr+114.4% vs Q1 FY26+2.9% vs Q4 FY26
Q1 FY27 operating margin: 12.3%+3.9 pts vs Q1 FY26−1.1 pts vs Q4 FY26
Q2 FY26 net profit (a year earlier): ₹14.7 CrRevenue ₹424 Cr
Q1 FY27 EPS (basic): ₹1.51

Questions

When will Viyash Scientific announce its Q2 FY27 results?

The date is not announced yet. Results for July–September 2026 are due by 14 November 2026 (45 days after the quarter, SEBI Regulation 33). Last year it reported Q2 FY26 on 14 November 2025.

What were Viyash Scientific's Q1 FY27 results?

Consolidated net profit attributable to shareholders was ₹65.9 crore, up 360.3% from ₹14.3 crore in Q1 FY26 and up 26.4% from ₹52.1 crore in Q4 FY26. Revenue from operations was ₹946 crore, up 114.4% year on year and up 2.9% from the previous quarter.

What was Viyash Scientific's net profit in FY26?

Consolidated net profit attributable to shareholders was ₹177 crore in FY26 (April 2025–March 2026), up 710.2% from ₹21.9 crore in FY25. It was a loss of ₹35.9 crore in FY24 and a loss of ₹121 crore in FY23.

What will Viyash Scientific's Q2 FY27 results be compared with?

With the same quarter a year earlier, Q2 FY26 (July–September 2025), when consolidated net profit attributable to shareholders was ₹14.7 crore and revenue from operations ₹424 crore. The latest quarter, Q1 FY27, had a net profit of ₹65.9 crore and revenue of ₹946 crore.

How has Viyash Scientific's profit changed over the last four quarters?

Net profit attributable to shareholders by quarter: ₹14.7 crore in Q2 FY26, ₹38.4 crore in Q3 FY26, ₹52.1 crore in Q4 FY26 and ₹65.9 crore in Q1 FY27. That is ₹171 crore over the four quarters, up 412.3% from ₹33.4 crore in the four quarters before. Revenue from operations: ₹424 crore, ₹858 crore, ₹920 crore and ₹946 crore.

What was Viyash Scientific's revenue in FY26?

Revenue from operations was ₹3,420 crore in FY26 (April 2025–March 2026), up 120.5% from ₹1,551 crore in FY25. It was ₹1,370 crore in FY24 and ₹1,421 crore in FY23: up 140.7% over three years, 34.0% a year on average.

Where do these Viyash Scientific figures come from?

From Viyash Scientific's own consolidated results filings to NSE, in ₹ crore as filed; the date from its board-meeting notices.

Consolidated figures from the company's filings to NSE. Every company's results dates this season are in the Q2 FY27 results calendar, part of Alpha Plus.